Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Is promotional financing available on Mayo Clinic Diet program purchases
Diabetes Drugs and Weight Loss
Reasons for Discontinuing GLP-1 Use Lapsed weight loss users said price and insurance coverage were the top reasons for discontinuing use
Latin America held a 3% share of the market in 2025 and is expected to grow at a significant CAGR of 14% during the projection period, driven by GLP-1 medications that are driving structural health and economic shifts across Latin America by curbing surging obesity and type-2 diabetes rates, spurring vast biopharma investments, and fundamentally changing consumer habits in the fast-moving consumer goods sector
However, investors may be concerned about the company's likelihood of bringing this drug to market quickly enough to capture a sizable customer base, given that many alternatives are already available or are rushing through development
